Maitreya Medica. (MAITREYA)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 73.11% aligns management with minority shareholders.
• ROCE of 10.77% is positive, showing the existing capital base still generates some operating return.
• Latest quarterly sales of ₹24 Cr provide a meaningful revenue base for a potential recovery.
• Small market cap of ₹134 Cr means even a modest absolute profit recovery could move earnings per share significantly.

Concerns

• P/E of 838.50 with near-zero net profit leaves no margin of safety.
• Profit growth of -102.40% confirms earnings have vanished; latest quarter net profit is ₹0 Cr.
• Piotroski F-score of 3/9 indicates weak financial health and deteriorating fundamentals.
• Sales are declining at -2.71% with zero dividend, so there is no income support while waiting.

AI Analysis

Looking at Maitreya Medica, the first thing that strikes me is the price. At ₹167.95, the market is asking me to pay 838 times earnings for a hospital whose profit has collapsed by 102.40%. Graham would call that speculation, not investment. The latest quarter captures the problem: sales of ₹24 Cr but net profit of essentially ₹0 Cr. There is no earnings engine running today. Sales growth is also negative at -2.71%, so this is not a temporary blip but a business losing momentum. ROCE at 10.77% is acceptable, but not a sign of a wide-moat franchise. The Piotroski F-score of 3/9 is a red flag; a strong business would show far more fundamental improvement. I also see no dividend, so the only possible return is price appreciation, which at this valuation is fragile. Promoter holding of 73.11% is encouraging because management has skin in the game, but high ownership cannot substitute for profitability. Without book value, ROE, and debt/equity data, I cannot judge the balance-sheet risk, and that lack of transparency makes me even more cautious. The 52-week range of ₹112.05 to ₹292.95 shows how emotional the market has been. I don't need to participate. In Buffett's words, it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price—here I see neither certainty nor a wonderful price. Maitreya Medica may someday recover, but I need evidence in the form of rising sales, positive net profit, and improved Piotroski score before I commit capital. This is a possible turnaround, not an investment for the patient value investor today.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer